Speaker Interview with Anna Karmann, Chief Medical Officer, AdvanCell

AdvanCell has amassed a great amount of funding recently from $18M in Federal Funding just this week and $112M Series C Financing. What led such financing?

We received non-dilutive federal funding for a clinical platform trial to accelerate the development of alpha therapy combinations in collaboration with leading academics and institutions. Our research has been awarded as it leverages novel technologies and innovative clinical approaches designed to transform patient care and enhance clinical outcomes.

I think being differentiated and having clinical data is key in this environment. AdvanCell’s proprietary production of 212Pb provides a competitive advantage and barrier to entry, paired with a global accelerated development strategy.

Could you share what’s to come for AdvanCell over the next 12 months?

AdvanCell will be very relevant, fueled by several catalysts, including data from our TheraPb trial.

What impact do you think Lead-212 will have on the field in the next 12 months?

The design elements and dosing strategies we implemented in our 212Pb TheraPb trial might encourage other RLT developers to seek out dose optimization early in development. As an alpha emitter with a short half-life, 212Pb has a unique immunogenic profile enabling novel combination therapies. 212Pb further encompasses the opportunity for isotope diversification, and supply chain risk mitigation.

What are you looking forward to at the 4th Targeted Radiopharmaceuticals Summit US?

I look forward to meeting and hearing from members of this exciting and growing community.

Learn more about Anna’s session and view the full 4th Targeted Radiopharmaceuticals Summit program here: https://ter.li/fpn1dh